{"id":"e7777","rwe":[{"pmid":"41181593","year":"2025","title":"Clinically approved immunotoxins targeting hematological cancers: \"the best of both worlds\".","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"40009571","year":"2025","title":"Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.","finding":"","journal":"Clinical and translational science","studyType":"Clinical Study"},{"pmid":"33355734","year":"2006","title":"Denileukin Diftitox.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"38022532","year":"2023","title":"Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"},{"pmid":"36047157","year":"2022","title":"[Preclinical and clinical researches of Denileukin Diftitox (Genetical Recombination) (Remitoro(®)), a novel agent for T-cell lymphoma].","finding":"","journal":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica","studyType":"Clinical Study"}],"tags":[{"label":"CD25-directed Cytotoxin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Interleukin-2 receptor","category":"target"},{"label":"IL2RA","category":"gene"},{"label":"IL2RB","category":"gene"},{"label":"IL2RG","category":"gene"},{"label":"L01XX29","category":"atc"},{"label":"Active","category":"status"},{"label":"Primary cutaneous T-cell lymphoma","category":"indication"},{"label":"Refractory peripheral T-cell lymphoma","category":"indication"},{"label":"Eisai Inc","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":["ONTAK®"],"company":"Eisai","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=E7777","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:31:28.664282+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:31:35.812890+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=E7777","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:31:36.129143+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interleukin-2 receptor binding agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:31:37.208016+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201550/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:31:36.869493+00:00"}},"allNames":"ontak","offLabel":[],"synonyms":["denileukin diftitox","ontak","E7272","E7777"],"timeline":[{"date":"1999-02-05","type":"positive","source":"DrugCentral","milestone":"FDA approval (Eisai Inc)"},{"date":"2021-03-23","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Eisai Co., Ltd.)"}],"aiSummary":"Ontak (E7777) is a CD25-directed cytotoxin, a small molecule drug developed by Eisai Inc. It targets the interleukin-2 receptor, a protein on the surface of certain cancer cells. Ontak is approved by the FDA for the treatment of primary cutaneous T-cell lymphoma and refractory peripheral T-cell lymphoma. It was first approved in 1999 and remains a patented product. As a cytotoxin, Ontak works by selectively killing cancer cells that express the interleukin-2 receptor.","brandName":"Ontak","ecosystem":[{"indication":"Primary cutaneous T-cell lymphoma","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":null},{"indication":"Refractory peripheral T-cell lymphoma","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Interleukin-2 receptor","novelty":"Follow-on","targets":[{"gene":"IL2RA","source":"DrugCentral","target":"Interleukin-2 receptor","protein":"Interleukin-2 receptor subunit alpha"},{"gene":"IL2RB","source":"DrugCentral","target":"Interleukin-2 receptor","protein":"Interleukin-2 receptor subunit beta"},{"gene":"IL2RG","source":"DrugCentral","target":"Interleukin-2 receptor","protein":"Cytokine receptor common subunit gamma"}],"modality":"Small Molecule","drugClass":"CD25-directed Cytotoxin","explanation":"","oneSentence":"","technicalDetail":"Ontak (denileukin diftitox) is a recombinant fusion protein consisting of interleukin-2 (IL-2) linked to diphtheria toxin. It binds to the IL-2 receptor on the surface of cancer cells, leading to the internalization of the toxin and subsequent cell death."},"commercial":{"launchDate":"1999","_launchSource":"DrugCentral (FDA 1999-02-05, EISAI INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5087","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=E7777","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=E7777","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T02:41:03.099381","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:31:38.420553+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"asparaginase","drugSlug":"asparaginase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"altretamine","drugSlug":"altretamine","fdaApproval":"1990-12-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"hydroxycarbamide","drugSlug":"hydroxycarbamide","fdaApproval":"1967-12-07","relationship":"same-class"},{"drugName":"pentostatin","drugSlug":"pentostatin","fdaApproval":"1991-10-11","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"masoprocol","drugSlug":"masoprocol","fdaApproval":"1992-09-04","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mitotane","drugSlug":"mitotane","fdaApproval":"1970-07-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"pegaspargase","drugSlug":"pegaspargase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"arsenic trioxide","drugSlug":"arsenic-trioxide","fdaApproval":"2000-09-25","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"anagrelide","drugSlug":"anagrelide","fdaApproval":"1997-03-14","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"omacetaxine mepesuccinate","drugSlug":"omacetaxine-mepesuccinate","fdaApproval":"2012-10-26","patentExpiry":"Oct 26, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"eribulin","drugSlug":"eribulin","fdaApproval":"2010-11-15","patentExpiry":"Jul 8, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"aflibercept","drugSlug":"aflibercept","fdaApproval":"2011-11-18","relationship":"same-class"},{"drugName":"venetoclax","drugSlug":"venetoclax","fdaApproval":"2016-04-11","patentExpiry":"Sep 6, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"enasidenib","drugSlug":"enasidenib","fdaApproval":"2017-08-01","patentExpiry":"Sep 16, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ivosidenib","drugSlug":"ivosidenib","fdaApproval":"2018-07-20","patentExpiry":"Oct 18, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selinexor","drugSlug":"selinexor","fdaApproval":"2019-07-03","patentExpiry":"Jul 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tagraxofusp","drugSlug":"tagraxofusp","fdaApproval":"2018-12-21","relationship":"same-class"},{"drugName":"lurbinectedin","drugSlug":"lurbinectedin","fdaApproval":"2020-06-15","patentExpiry":"May 29, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tazemetostat","drugSlug":"tazemetostat","fdaApproval":"2020-01-23","patentExpiry":"Sep 12, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"e7777","indications":{"approved":[{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral","snomedId":400122007,"regulator":"FDA"},{"name":"Refractory peripheral T-cell lymphoma","source":"DrugCentral","snomedId":109977009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"asparaginase","brandName":"asparaginase","genericName":"asparaginase","approvalYear":"1994","relationship":"same-class"},{"drugId":"altretamine","brandName":"altretamine","genericName":"altretamine","approvalYear":"1990","relationship":"same-class"},{"drugId":"hydroxycarbamide","brandName":"hydroxycarbamide","genericName":"hydroxycarbamide","approvalYear":"1967","relationship":"same-class"},{"drugId":"pentostatin","brandName":"pentostatin","genericName":"pentostatin","approvalYear":"1991","relationship":"same-class"},{"drugId":"masoprocol","brandName":"masoprocol","genericName":"masoprocol","approvalYear":"1992","relationship":"same-class"},{"drugId":"mitotane","brandName":"mitotane","genericName":"mitotane","approvalYear":"1970","relationship":"same-class"},{"drugId":"pegaspargase","brandName":"pegaspargase","genericName":"pegaspargase","approvalYear":"1994","relationship":"same-class"},{"drugId":"arsenic-trioxide","brandName":"arsenic trioxide","genericName":"arsenic trioxide","approvalYear":"2000","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"},{"drugId":"anagrelide","brandName":"anagrelide","genericName":"anagrelide","approvalYear":"1997","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04855253","phase":"PHASE1,PHASE2","title":"Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL","status":"SUSPENDED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2021-06-09","conditions":["DLBCL","Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","DLBCL Arising From Follicular Lymphoma"],"enrollment":30,"completionDate":"2026-12"},{"nctId":"NCT05200559","phase":"PHASE1,PHASE2","title":"T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Alexander B Olawaiye, MD","startDate":"2022-09-30","conditions":["Epithelial Ovarian Cancer"],"enrollment":70,"completionDate":"2027-12"},{"nctId":"NCT01871727","phase":"PHASE3","title":"A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2013-05-30","conditions":["Persistent or Recurrent Cutaneous T-Cell Lymphoma"],"enrollment":112,"completionDate":"2021-12-14"},{"nctId":"NCT05137847","phase":"","title":"A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2021-05-24","conditions":["Lymphoma, T-cell, Peripheral","Lymphoma, T-cell, Cutaneous"],"enrollment":118,"completionDate":"2023-03-17"},{"nctId":"NCT02676778","phase":"PHASE2","title":"Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2016-03-28","conditions":["Peripheral T-cell Lymphoma","Cutaneous T-cell Lymphoma"],"enrollment":45,"completionDate":"2019-04-26"},{"nctId":"NCT01401530","phase":"PHASE1","title":"E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-07","conditions":["Peripheral T-Cell Lymphoma"],"enrollment":13,"completionDate":"2016-01"},{"nctId":"NCT01355783","phase":"PHASE3","title":"A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma","status":"WITHDRAWN","sponsor":"Eisai Inc.","startDate":"2011-03","conditions":["Peripheral T-Cell Lymphoma"],"enrollment":0,"completionDate":"2014-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"14092","NDDF":"007748","UNII":"25E79B5CTM","INN_ID":"7680","RXNORM":"214470","UMLSCUI":"C0717670","chemblId":"CHEMBL1201550","ChEMBL_ID":"CHEMBL1201550","KEGG_DRUG":"D03682","DRUGBANK_ID":"DB00004","SNOMEDCT_US":"125700002","IUPHAR_LIGAND_ID":"7044","MESH_SUPPLEMENTAL_RECORD_UI":"C078456"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1999-","companyName":"Eisai Inc","relationship":"Original Developer"},{"period":"2021","companyName":"Eisai Co., Ltd.","relationship":"PMDA Licensee"}],"publicationCount":9,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01XX29","allCodes":["L01XX29"]},"biosimilarFilings":[],"originalDeveloper":"Eisai Inc","recentPublications":[{"date":"2025","pmid":"41181593","title":"Clinically approved immunotoxins targeting hematological cancers: \"the best of both worlds\".","journal":"Frontiers in pharmacology"},{"date":"2025 Mar","pmid":"40009571","title":"Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.","journal":"Clinical and translational science"},{"date":"2006","pmid":"33355734","title":"Denileukin Diftitox.","journal":""},{"date":"2023","pmid":"38022532","title":"Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.","journal":"Frontiers in immunology"},{"date":"2022","pmid":"36047157","title":"[Preclinical and clinical researches of Denileukin Diftitox (Genetical Recombination) (Remitoro(®)), a novel agent for T-cell lymphoma].","journal":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Eisai","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"1999","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:31:38.420553+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}